Highlights Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
18,700 ^KRW	+0.11%		-4.40%	-28.35%

05-20	Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	CI
05-16	Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	05-19	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	04-25	CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	04-25	CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer	04-22	CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection	04-19	CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	03-10	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.	30/08/23	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.	24/08/22	CI
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA	26/05/22	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials	12/05/22	CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills	29/12/21	MT
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hyundai Bioscience Co., Ltd.

Equities

A048410

KR7048410005

Highlights

Filters